The global HIV response has made extraordinary progress, yet the fundamentals of prevention remain fragile. Nearly 40 million people are living with HIV, and new infections continue at a pace that threatens global targets to end AIDS as a public health threat. Daily oral PrEP is one of the most effective tools available, but its success depends on sustained adherence—something health systems and individuals alike struggle to support over time.

A once-monthly oral prevention pill represents more than a clinical innovation. It offers a rare opportunity to rethink how prevention fits into people’s lives, and how systems can deliver it—reshaping what is possible in the next phase of the HIV response.
MK-8527, Merck’s experimental once-monthly pill for HIV prevention, is now being tested in Phase III clinical trials after earlier Phase II results supported moving it forward as a monthly option. Public information indicates that two large studies are taking place across multiple countries and groups, including women and adolescent girls in sub-Saharan Africa and other people at high risk of acquiring HIV.

The potential benefit is simple but important: a pill taken only once a month could give people more choice, make prevention easier to maintain than a daily pill, and offer a more private option for those who want HIV protection without injections or daily dosing.

The product is not novel, but the pathway must be.

The opportunity and possibilities for people, communities, and global health as a whole from MK-8527 are massive. Not only in the product itself, but in what it could unlock for HIV prevention systems if countries are prepared to introduce it quickly and equitably. For too long, global health has treated innovation as synonymous with the molecule. But successful introduction depends just as much on what happens after clinical promise is established: whether countries have the regulatory pathways, financing plans, delivery models, provider guidance, and demand-generation strategies needed to turn a promising product into a practical option at scale.

That is especially true for a once-monthly oral PrEP product, which also be easier to integrate into existing service platforms than some clinic-dependent long-acting options, particularly in settings where health systems are already stretched.

But none of that happens automatically. New HIV prevention products do not reach the people who would benefit most simply because the science is strong. They reach scale when markets are shaped intentionally, when supply and distribution models match user preferences, and when regulatory and policy processes move with urgency rather than delay. The rollout of long-acting injectable cabotegravir (CAB-LA) illustrates this reality. Despite strong clinical evidence, uptake depended on coordinated efforts to secure financing, accelerate regulatory approvals, train providers, create delivery channels, and build awareness among potential users. Where those systems were put in place early, countries moved faster to introduce the product; where they were not, access lagged behind the science.

To make it a reality, there must be innovations in the marketing, distribution, and country regulatory processes to ensuring once-monthly oral PrEP is taken up in the countries that would most benefit from it. In many high-burden settings, the challenge is not only product approval. It is building the bridge from approval to uptake.What market shaping looks like in practice

First, countries and partners need an early market access strategy. That means anticipating demand, identifying priority geographies, and aligning procurement and pricing pathways before launch. It also means thinking beyond public-sector channels alone. If monthly oral PrEP is to reach people who need privacy, flexibility, and convenience, then distribution models should include differentiated delivery through private providers, pharmacies, community-based platforms, and other trusted access points where national policy allows.

Second, the product introduction strategy must be built around user-centred marketing and demand generation. The value proposition of once-monthly oral PrEP is not just pharmacological. It is behavioural and practical. Communications, provider counselling, and community engagement will need to explain clearly who this option is for, how it fits within a broader prevention choice basket, and why it may be a better fit for some users than daily oral PrEP or injectable alternatives. If positioning is weak, uptake will be weak, regardless of clinical performance.

Third, regulatory innovation matters. Countries that adopt efficient, science-based regulatory pathways can dramatically shorten the time between global evidence and local availability. That includes reliance and recognition mechanisms, streamlined dossier review, rapid guideline updates, and alignment across national regulatory authorities, essential medicines processes, and HIV prevention policies. For many countries, regulatory readiness will be one of the decisive factors determining whether this product arrives early or years late.

Ultimately, success will live at this intersection of innovation and implementation.

For MK-8527 and similar innovations, that means supporting governments and partners with the practical decisions that determine whether access is timely, affordable, and equitable: which channels to use, which populations to prioritise, how to finance scale-up, how to train providers, and how to adapt national systems without creating new bottlenecks.

The global HIV response has never advanced through science alone. It has advanced when scientific breakthroughs were matched by policy courage, smart market design, and country-led implementation. Once-monthly oral PrEP may prove to be one of the most important prevention innovations now in development. But if it is to change the trajectory of the epidemic in the countries carrying the greatest burden, we must innovate around the product as seriously as we innovate within it.

That is the opportunity as we see it: not simply helping launch a new product, but helping build the pathways that allow promising innovation to reach people faster, more fairly, and at scale.